Laboratorios Farmaceuticos Rovi (ROVI) Aktievy
Laboratorios Farmaceuticos Rovi, S.A. tillverkar, säljer och marknadsför farmaceutiska produkter i Spanien, EU, OECD-länderna och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 6/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 3/6 |
Belöningar
Riskanalys
ROVI Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€51.25
FV
15.6% övervärderad intrinsisk rabatt4.00%
Revenue growth p.a.
157
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Laboratorios Farmaceuticos Rovi, S.A. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €59.25 |
| 52 veckors högsta | €86.70 |
| 52 veckors lägsta | €51.65 |
| Beta | 0.22 |
| 1 månads förändring | 2.42% |
| 3 månaders förändring | -25.38% |
| 1 års förändring | 9.32% |
| 3 års förändring | 31.96% |
| 5 års förändring | -1.74% |
| Förändring sedan börsintroduktionen | 492.50% |
Senaste nyheter och uppdateringar
Analysartikel • 5h
We Think That There Are Issues Underlying Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings
Unsurprisingly, Laboratorios Farmaceuticos Rovi, S.A.'s ( BME:ROVI ) stock price was strong on the back of its healthy...Analysartikel • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...Recent updates
Analysartikel • 5h
We Think That There Are Issues Underlying Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings
Unsurprisingly, Laboratorios Farmaceuticos Rovi, S.A.'s ( BME:ROVI ) stock price was strong on the back of its healthy...Analysartikel • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...
Uppdatering av berättelse • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.Uppdatering av berättelse • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Analysartikel • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Uppdatering av berättelse • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.Uppdatering av berättelse • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.Uppdatering av berättelse • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.Uppdatering av berättelse • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.Uppdatering av berättelse • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.Uppdatering av berättelse • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.Analysartikel • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Analysartikel • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analysartikel • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analysartikel • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Ny berättelse • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Analysartikel • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Analysartikel • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analysartikel • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...Analysartikel • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...Analysartikel • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analysartikel • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...Analysartikel • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...Analysartikel • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...Analysartikel • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysartikel • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...Analysartikel • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...Analysartikel • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...Aktieägarnas avkastning
| ROVI | ES Pharmaceuticals | ES Marknad | |
|---|---|---|---|
| 7D | 2.0% | 1.3% | 2.4% |
| 1Y | 9.3% | 6.7% | 33.1% |
Avkastning vs industri: ROVI översteg Spanish Pharmaceuticals branschen som gav 6.7 % under det senaste året.
Avkastning vs Marknaden: ROVI presterade sämre än Spanish marknaden som gav 33.1 % under det senaste året.
Prisvolatilitet
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 3.2% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.7% |
| 10% least volatile stocks in ES Market | 0.7% |
Stabil aktiekurs: ROVI s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Spanish.
Volatilitet över tid: ROVI s veckovolatilitet ( 5% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Spanish aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1946 | 2,470 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. tillverkar, säljer och marknadsför farmaceutiska produkter i Spanien, EU, OECD-länderna och internationellt. Företaget erbjuder receptbelagda produkter, bland annat Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler och Volutsa. Företaget tillhandahåller också sjukhusprodukter, såsom Iomeron och Iopamiro, Multihance och Y Prohance, Sonovue, Empowercta+, Empowermr och CT Express, katetervård under varumärket Fibrilin samt natriumheparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Sammanfattning av grunderna
| ROVI grundläggande statistik | |
|---|---|
| Börsvärde | €3.03b |
| Vinst(TTM) | €185.18m |
| Intäkter(TTM) | €773.05m |
16.4x
P/E-förhållande3.9x
P/S-förhållandeÄr ROVI övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ROVI resultaträkning (TTM) | |
|---|---|
| Intäkter | €773.05m |
| Kostnad för intäkter | €272.63m |
| Bruttovinst | €500.42m |
| Övriga kostnader | €315.24m |
| Intäkter | €185.18m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 3.62 |
| Bruttomarginal | 64.73% |
| Nettovinstmarginal | 23.95% |
| Skuld/egenkapitalförhållande | 15.0% |
Hur har ROVI utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.6%
Aktuell utdelningsavkastning26%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/30 10:05 |
| Aktiekurs vid dagens slut | 2026/07/30 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Laboratorios Farmaceuticos Rovi, S.A. bevakas av 13 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |